Home / News (Page 3)

News

Success for the therapeutic vaccine INVAC-1 in cancer

With 7 million raised in the last year and excellent results in terms of tolerance and innocuity, Invectys opens up new hopes in cancer immunotherapy   Paris,…

Read more

Invectys strengthens its intellectual property

Invectys files a patent on the acquisition of antibodies against an immune checkpoint expressed in all types of cancers and strengthens its HLA-G intellectual property…

Read more

Invectys raises 7 million euros more for clinical devel...

With more than 17 million euros raised in total Invectys also benefits from 850,000€ in financing from Bpifrance. Invectys announces fundraising of an additional…

Read more

Invectys starts the third dose level of its phase I ...

Invectys starts the third dose level of its phase I clinical trial evaluating INVAC-1, an innovative anti-cancer therapeutic vaccine  A new clinical hope in cancer…

Read more

Invectys raises 1.7 million Euros more to finance the ...

Invectys raises 1.7 million Euros more to  finance the clinical development of its therapeutic cancer vaccine With a total of 10 million euros raised, new premises,…

Read more

Invectys Initiates Phase I Clinical Trial Evaluating IN...

Invectys Initiates Phase I Clinical Trial Evaluating INVAC-1 Therapeutic Vaccine for Cancer Patients A new clinical hope in cancer immunotherapy Paris, May 12th,…

Read more

Invectys receives ANSM approval to start clinical trial...

Invectys receives ANSM approval to start clinical trial for INVAC-1, its leading anticancer immunotherapy INVAC-1 is an anticancer candidate vaccine targeting…

Read more

Press Release – Invectys Initiates Phase I Clinical T...

A new clinical hope in cancer immunotherapy Paris, May 12th, 2015 – Invectys announces today that it has initiated a phase I clinical trial of its immunotherapeutic…

Read more